Fungal metabolic processes

Fungal metabolic processes encompass the diverse biochemical reactions essential for fungi to grow, reproduce, and survive in their environment. Unlike plants, fungi are heterotrophic, absorbing nutrients and converting them into energy and cellular components through primary metabolic pathways like glycolysis, the citric acid cycle, and biosynthesis of carbohydrates, proteins, and lipids. Secondary metabolism produces specialized compounds for adaptation and defense. These processes are critical for fungal viability and pathogenicity, making them a broad and important area for therapeutic intervention against fungal infections (mycoses). Antifungal drugs target various unique aspects of fungal metabolism, such as the synthesis of ergosterol (a fungal-specific sterol analogous to cholesterol in humans) or components of the fungal cell wall, which are absent in human cells. However, the broad nature of 'fungal metabolic processes' means it is not a single molecular target but rather a collection of numerous enzymes, transporters, and structural components within these pathways. Targeting these processes can lead to safety concerns due to the eukaryotic similarity between fungal and human cells, resulting in potential side effects like liver or kidney damage, and the emergence of drug resistance.

Other names

Fungal metabolismFungal metabolic pathways

Drugs targeting fungal metabolic processes primarily act by inhibiting the synthesis of essential fungal components like ergosterol (e.g., azoles, allylamines) or the fungal cell wall (e.g., echinocandins). Other mechanisms include directly binding to ergosterol to disrupt membrane integrity (e.g., polyenes), interfering with DNA/RNA synthesis (e.g., flucytosine), or inhibiting microtubule polymerization (e.g., griseofulvin). These actions disrupt vital metabolic pathways necessary for fungal growth, reproduction, and survival.